Genprex (GNPX) Competitors $0.29 -0.02 (-6.77%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.30 +0.01 (+1.75%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GNPX vs. PLUR, SCYX, RANI, TPST, KZR, FGEN, GRCE, ALXO, PULM, and COEPShould you be buying Genprex stock or one of its competitors? The main competitors of Genprex include Pluri (PLUR), SCYNEXIS (SCYX), Rani Therapeutics (RANI), Tempest Therapeutics (TPST), Kezar Life Sciences (KZR), FibroGen (FGEN), Grace Therapeutics (GRCE), ALX Oncology (ALXO), Pulmatrix (PULM), and Coeptis Therapeutics (COEP). These companies are all part of the "pharmaceutical products" industry. Genprex vs. Its Competitors Pluri SCYNEXIS Rani Therapeutics Tempest Therapeutics Kezar Life Sciences FibroGen Grace Therapeutics ALX Oncology Pulmatrix Coeptis Therapeutics Genprex (NASDAQ:GNPX) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, community ranking, valuation and earnings. Which has higher earnings and valuation, GNPX or PLUR? Pluri has higher revenue and earnings than Genprex. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenprexN/AN/A-$30.86MN/AN/APluri$1.03M33.26-$20.89M-$5.53-0.79 Is GNPX or PLUR more profitable? Genprex has a net margin of 0.00% compared to Pluri's net margin of -3,551.49%. Genprex's return on equity of -409.48% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets GenprexN/A -409.48% -269.17% Pluri -3,551.49%-2,778.13%-83.61% Which has more volatility and risk, GNPX or PLUR? Genprex has a beta of -0.41, suggesting that its stock price is 141% less volatile than the S&P 500. Comparatively, Pluri has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Does the MarketBeat Community prefer GNPX or PLUR? Genprex received 198 more outperform votes than Pluri when rated by MarketBeat users. Likewise, 65.25% of users gave Genprex an outperform vote while only 50.00% of users gave Pluri an outperform vote. CompanyUnderperformOutperformGenprexOutperform Votes19965.25% Underperform Votes10634.75% PluriOutperform Votes150.00% Underperform Votes150.00% Do insiders & institutionals believe in GNPX or PLUR? 14.1% of Genprex shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 8.5% of Genprex shares are owned by insiders. Comparatively, 25.9% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts recommend GNPX or PLUR? Pluri has a consensus target price of $12.00, indicating a potential upside of 173.35%. Given Pluri's stronger consensus rating and higher possible upside, analysts clearly believe Pluri is more favorable than Genprex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Pluri 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to GNPX or PLUR? In the previous week, Genprex and Genprex both had 2 articles in the media. Genprex's average media sentiment score of 0.43 equaled Pluri'saverage media sentiment score. Company Overall Sentiment Genprex Neutral Pluri Neutral SummaryPluri beats Genprex on 9 of the 13 factors compared between the two stocks. Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGenprexPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.12M$6.88B$5.57B$8.50BDividend YieldN/A2.48%5.27%4.17%P/E RatioN/A8.4626.7519.66Price / SalesN/A261.91403.98152.07Price / CashN/A65.8538.2534.64Price / Book0.066.526.964.59Net Income-$30.86M$143.26M$3.23B$248.23M7 Day Performance1.50%-0.21%-1.22%-1.07%1 Month Performance23.27%10.62%6.34%2.59%1 Year Performance-86.55%3.63%33.05%13.50% Genprex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGenprex1.2909 of 5 stars$0.29-6.8%N/A-86.5%$8.12MN/A0.0020Short Interest ↑Gap UpPLURPluri2.2598 of 5 stars$4.39-7.6%$12.00+173.3%-19.4%$34.39M$1.03M-0.78150Short Interest ↑SCYXSCYNEXIS0.5834 of 5 stars$0.86-6.3%N/A-60.4%$33.56M$2.63M-1.1660Positive NewsRANIRani Therapeutics2.1089 of 5 stars$0.57+2.5%$9.40+1,537.3%-87.0%$33M$1.20M-0.54110Negative NewsGap UpTPSTTempest Therapeutics2.7781 of 5 stars$8.95+8.5%$30.00+235.2%-82.5%$32.95MN/A-5.8520High Trading VolumeKZRKezar Life Sciences4.5652 of 5 stars$4.45+1.1%$39.50+787.6%-32.7%$32.51M$7M-0.3460Positive NewsFGENFibroGen4.5462 of 5 stars$0.32+2.0%$10.00+3,029.9%-76.4%$32.28M$7.00M-0.26570News CoverageStock SplitGap DownGRCEGrace Therapeutics2.4985 of 5 stars$3.16+6.4%$12.00+279.7%N/A$32.04MN/A-2.72N/ANews CoverageUpcoming EarningsGap DownHigh Trading VolumeALXOALX Oncology2.8998 of 5 stars$0.58-0.1%$3.30+470.2%-93.6%$30.90MN/A-0.1940Positive NewsAnalyst RevisionGap UpPULMPulmatrix0.3991 of 5 stars$8.44-5.1%N/A+315.4%$30.81M$1.92M-3.2020Positive NewsCOEPCoeptis Therapeutics1.3488 of 5 stars$8.75-2.2%N/A+27.1%$30.75M$62.87K-1.512Positive News Related Companies and Tools Related Companies PLUR Competitors SCYX Competitors RANI Competitors TPST Competitors KZR Competitors FGEN Competitors GRCE Competitors ALXO Competitors PULM Competitors COEP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNPX) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
